Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-27 16:49:17 - browse：8955

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Why the quest to eradicate polio has stumbled

leisure time

WSS

In age of alternative facts, a scholarly course on calling out crap

Covid’s new normal has set in amid another rise in cases

DIEP, the 'gold standard' of breast reconstruction, is under threat

People with substance use disorder deserve online privacy

David Liu startup to focus on CRISPR delivery

Free Covid tests will again be offered to all U.S. households

knowledge

Wikipedia

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to save PrEP access — and even expand it

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Akili changes sales model for its ADHD video game treatment

Medicare proposal to cover medical devices draws a mixed reaction

How to save PrEP access — and even expand it

In age of alternative facts, a scholarly course on calling out crap

Bright Health sells Medicare Advantage business to Molina

Cancer drug shortages should be causing more outrage

Supreme Court strikes down use of affirmative action

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Why the drug industry's warnings on the IRA's impact fall short

Guidelines to prevent youth baseball injuries need more muscle

Medical records are filled with copy

Moonlake's readout produced a cash windfall. Risks remain

Akili changes sales model for its ADHD video game treatment

hotspot

knowledge

leisure time

focus